Know Cancer

forgot password

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial

Phase 2
18 Years
Not Enrolling
Diffuse Large-Cell Lymphoma

Thank you

Trial Information

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial

In preclinical studies, pixantrone has shown significantly less cardiotoxicity than other
anthracyclines or anthracenediones. In addition, patients with relapsed disease, who have
received prior maximum doses of anthracyclines, have tolerated high doses of pixantrone with
minimal added cardiotoxicity. Pixantrone is currently being studied in a Phase III study in
3rd line aggressive NHL.

Inclusion Criteria:

1. Previously untreated and histologically confirmed diffuse large B-cell lymphoma
according to REAL/WHO classification.

2. Stage II, III or IV disease

3. CD20+

4. Age ≥ 18 years

5. ECOG performance status ≤ 2

6. At least one objectively bidimensionally measurable lesion as demonstrated by CT,
spiral CT, or MRI that can be followed for response as target lesion. Patients with
the following sites of disease are NOT eligible:

- Patients with only skin lesions or only palpable lymph nodes.

- Patients with spleen or bone marrow as only site of disease.

7. Life expectancy ≥ 3 months

8. Serum bilirubin ≤ 1.5 x the institution's upper limit normal (ULN) and creatinine ≤
2.0 ULN and AST or ALT ≤ 2.0 x the institution's ULN. If hepatic involvement by
lymphoma is present, AST or ALT may be ≤ 5.0 x the institution's ULN.

9. LVEF ≥ 50% determined by MUGA scan.

10. Ability to comply with the visit schedule and assessments required by the protocol.

11. Signed approved informed consent, with understanding of study procedures.

Exclusion Criteria:

1. Any prior chemotherapy (except intrathecal chemotherapy at diagnosis and pretreatment
corticosteroid therapy) or radiotherapy: Patients may receive corticosteroid
pretreatment therapy for up to 7 days after randomization, pending Investigator's
decision to reduce tumor burden.

2. Histological diagnosis of T-cell lymphoma or any B-cell lymphoma other than diffuse
large B-cell.

3. History of indolent lymphoma

4. Active CNS involvement based on clinical evaluation .

5. HIV-related lymphoma.

6. Major thoracic and/or abdominal surgery within the 4 weeks before randomization from
which the patient has not fully recovered except for diagnosis of NHL. Patients who
have had minor surgery may be enrolled after a ≥ 1 week recovery period except for
diagnosis of NHL.

7. Clinically significant cardiovascular abnormalities

8. Serious (NCI CTCAE grade 3-4) intercurrent infection at randomization or deep seated
or systemic mycotic infections.

9. Clinical symptoms suggesting unresolved HIV, HBV or HCV infection. Patients with
seropositivity presumed to be due to prior vaccination against Hepatitis B virus or
resolved infection will not be excluded.

10. Active or history of another malignancy except cured basal cell carcinoma of skin or
carcinoma in situ of uterine cervix. Patients who have been in remission from another
previous malignancy for >5 years will be considered eligible.

11. Known hypersensitivity to the excipients or the study drugs that the patient will

12. Any contraindications to the study drugs as described in the Summary of Product
Characteristics or package inserts. 13. Neurological contraindication to vincristine
(e.g. peripheral neuropathy).

14. Any condition which, in the judgment of the Investigator, would place the subject at
undue risk, interfere with the results of the study, or make the subject otherwise
unsuitable. 15. General status that, in the opinion of the Investigator does not permit
the administration of eight courses of CHOP-R/CPOP-R. 16. Treatment with any other
investigational study drug within 30 days before randomization. Patient must have
recovered from all side effects of other investigational therapy. 17. Potentially fertile
men and women and their sexual partners not willing to use adequate contraception as
defined by the Investigator during the study and for 6 months after the last day of study
drug administration.

18. Any circumstance at the time of study entry that would preclude completion of the
study or the required follow-up.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.

Outcome Time Frame:

Subjects followed for 5 years post treatment

Safety Issue:


Principal Investigator

Gabor Jurida, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Cell Therapeutics


United States: Food and Drug Administration

Study ID:




Start Date:

November 2005

Completion Date:

May 2012

Related Keywords:

  • Diffuse Large-Cell Lymphoma
  • lymphoma
  • NHL
  • large cell
  • phase II
  • CHOP R
  • CPOP R
  • non Hodgkins
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell



Loma Linda University Medical Center Loma Linda, California  92354
Thompson Cancer Survival Center Knoxville, Tennessee  37916
Southwest Regional Cancer Center Austin, Texas  78705
Rocky Mountain Cancer Center Denver, Colorado  80218
Our Lady of Mercy Medical Center Bronx, New York  10466
John B. Amos Cancer Center Columbus, Georgia  31904
Consultants in Blood Disorders and Cancer Louisville, Kentucky  40207
Watson Clinic Lakeland, Florida  33805
Sharp Memorial Hospital San Diego, California  92123
Greater Baltimore Medical Center Baltimore, Maryland  21204
Duke University Medical Center Durham, North Carolina  27710
Osceola Cancer Center Kissimmee, Florida  34741
Charleston Cancer Center Charleston, South Carolina  29406
Broward Oncology Associates Ft. Lauderdale, Florida  33308
Sarah Cannon Cancer Center Nashville, Tennessee  37203
Oncology Partners Network Cincinnati, Ohio  45238
Dayton Clinical Oncology Program Dayton, Ohio  45420
The Center for Cancer and Blood Disorders Fort Worth, Texas  76104
Hematology Oncology Associates of the Treasure Coast Port St. Lucie, Florida  34952
Western Kentucky Hematology/Oncology Group Paducah, Kentucky  42003
Nevada Cancer Institute Las Vegas, Nevada  89135
The Family Cancer Center Collierville, Tennessee  38017
Watson Clinic for Cancer Care and Research Lakeland, Florida  33805
Northwest Kaiser Permanente Portland, Oregon  97227
Northern Utah Hematology Oncology, P.C. Ogden, Utah  84403
Maryland Hematology/Oncology Associates, PA Baltimore, Maryland  21236
Center for Cancer and Blood Disorders, P.C. Bethesda, Maryland  20817-7847
Hubert H Humphrey Cancer Center Robbinsdale, Minnesota  55422
Hematology/Oncology Group of Orange County Orange, California  92868
Bay Medical Oncology & Hematology Concord, California  94520
Hazel Hawkins Hospital, Dept. of Medical Oncology Hollister, California  95020
UCSD Moore's Cancer Center-Blood & Marrow Transplantation Division La Jolla, California  92093
The Center of Hematology and Oncology Boca Raton, Florida  33486
Memorial Cancer Institute Pembroke Pines, Florida  33028
Oncology Hematology Associates of West Broward Tamarac, Florida  33321
Hematology Oncology Specialists Tampa, Florida  33607
Columbus Clinic Columbus, Georgia  39101
Oncology Hematology of Northern Illinois Gurnee, Illinois  60031
Mid-Illinois Hematology & Oncology Associates Normal, Illinois  61761
Our Lady of the Lake Regional Medial Center, Hematology Oncology Baton Rouge, Louisiana  70808
Frederick Memorial Hospital Cancer Center Frederick, Maryland  21701
Tufts-New England Medical Center-The Neely Ctr for Clinical Cancer Research Boston, Massachusetts  02111
North Missssppi Hematology Oncology Associates Tupelo, Mississippi  38801
Capital Comprehensive Cancer Care Jefferson City, Missouri  65109
Southeast Nebraska Hematology and Oncology Consultants, P.C. Lincoln, Nebraska  68510
New Mexico Hematology/Oncology Consultants Albuquerque, New Mexico  87109
Jacobi Medical Center Phase I Oncology Bronx, New York  10461
Cancer Care Center New Albany, New York  47150
St. Luke's Roosevelt Hospital New York City, New York  10019
Interlake Foundation, Inc. Rochester, New York  14623
Brody School of Medicine at East Carolina University - Leo W. Jenkins Cancer Center Greenville, North Carolina  27858
Cancer Treatment & Research Mid-Dakota Clinic Bismark, North Dakota  58501
Summa Health Systems Hospitals Akron, Ohio  44304
Barberton Citizen's Hospital Barberton, Ohio  44203
Berks Hematology-Oncology Associates Ltd. Reading, Pennsylvania  19612
Low County Hematology & Oncology Mount Pleasant, South Carolina  29464
Texas Hematology Oncology Center Dallas, Texas  75234
Multicare Oncology Hematology Specialists Tacoma, Washington  98405